New hope for ALS patients: major drug trial aims to slow devastating disease
NCT ID NCT07322003
Summary
This Phase 3 trial is testing whether the drug pridopidine can slow the progression of ALS (amyotrophic lateral sclerosis) in adults. The study will involve 500 participants who will take either pridopidine or a placebo daily for 48 weeks, followed by another 48 weeks where everyone receives the active drug. Researchers will measure changes in physical function, speech, breathing, and survival to determine if pridopidine helps control this devastating disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sean M. Healey & AMG Center for ALS
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Somnos Clinical Research
RECRUITINGLincoln, Nebraska, 68506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Texas Neurology
RECRUITINGDallas, Texas, 75206, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.